Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A
{{output}}
The need to reduce the burden of injections, and improve adherence and clinical outcomes in haemophilia A led to the development of recombinant FVIII products endowed with an extended plasma half-life (EHL-rFVIII) in comparison with standard half-life products... ...
